Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Booz Allen: Too Soon To Say If FDA Process Reforms Are Working

This article was originally published in The Gray Sheet

Executive Summary

FDA's device center has implemented all the recommendations Booz Allen Hamilton has made in the past several years to improve the review process, the consulting firm said in its latest independent assessment report. But it is still too early to conclude if the changes have led to significant improvements.

You may also be interested in...

CDRH Passes Independent Review With Flying Colors

The independent reviewers at Booz Allen Hamilton say US FDA’s device center has not only successfully implemented all 11 recommendations the contractors made as part of the prior user-fee program, but they’ve noticed significant improvements at the center as a result. The reviewers have also added new recommendations in a final report to improve procedures linked to IT systems and staff training.

Initial Survey Results Show Overwhelming Satisfaction With FDA Device Center Customer Service

While there are still a few months to go before the US FDA's Center for Devices and Radiological Health closes its customer service survey, the initial results look to be trending in the agency's favor. With almost nine-in-ten respondents giving a positive review, the results support the agency's efforts to improve customer service.

Big Uptick In Withdrawn 510(k)s Highlighted In Booz Allen Assessment

The consulting group issued its final assessment of FDA’s device review program following a year-long examination; it includes 11 recommendations for improvements. Among the new directives that were not included in Booz Allen’s interim report in December: FDA should perform a large study of withdrawn device submissions to figure out how to limit the growing practice.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts